{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:18:58Z","timestamp":1793215138784,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1136\/ard-2022-223715","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T05:02:43Z","timestamp":1679461363000},"page":"901-910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":125,"title":["Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance"],"prefix":"10.1016","volume":"82","clinical-trial-number":[{"clinical-trial-number":"nct02092467","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01262118","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01484561","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00147498","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00413660","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00550446","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00603512","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00687193","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01164579","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00976599","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01059864","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01359150","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02147587","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00960440","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00847613","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00814307","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00856544","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00853385","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01039688","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02281552","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02187055","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02831855","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00413699","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00661661","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00787202","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01465763","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01458951","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01458574","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01470612","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01877668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01882439","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01976364","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02092467","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lars Erik","family":"Kristensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Yndestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Modesto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Benda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-223715_bib1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223715_bib2","author":"FDA"},{"key":"10.1136\/ard-2022-223715_bib3","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"10.1136\/ard-2022-223715_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaccao.2020.12.003","article-title":"Cardiovascular risk factors are associated with future cancer","volume":"3","author":"Lau","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1136\/ard-2022-223715_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from oral surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"suppl 9","key":"10.1136\/ard-2022-223715_bib6","article-title":"Risk factors for major adverse cardiovascular events in patients aged \u2265 50 years with RA and \u2265 1 additional cardiovascular risk factor: results from a phase 3b\/4 randomized safety study of tofacitinib vs TNF inhibitors [abstract]","volume":"73","author":"Charles-Schoeman","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223715_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled oral surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223715_bib8","author":"European medicines agency"},{"key":"10.1136\/ard-2022-223715_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c117","article-title":"Is a subgroup effect believable? updating criteria to evaluate the credibility of subgroup analyses","volume":"340","author":"Sun","year":"2010","journal-title":"BMJ"},{"key":"10.1136\/ard-2022-223715_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001595","article-title":"Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure","volume":"7","author":"Burmester","year":"2021","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223715_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/acr2.1010","article-title":"Persistence of tofacitinib in the treatment of rheumatoid arthritis in open-label, long-term extension studies up to 9.5 years","volume":"1","author":"Pope","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/ard-2022-223715_bib12","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12325-019-01145-8","article-title":"Long-term safety of adalimumab in 29,967 adult patients from global clinical trials across multiple indications: an updated analysis","volume":"37","author":"Burmester","year":"2020","journal-title":"Adv Ther"},{"key":"10.1136\/ard-2022-223715_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000942","article-title":"Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials","volume":"5","author":"Curtis","year":"2019","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223715_bib14","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223715_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000213","article-title":"Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab","volume":"2","author":"Rubbert-Roth","year":"2016","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223715_bib16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3899\/jrheum.120906","article-title":"Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program","volume":"40","author":"Weinblatt","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223715_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40744-019-00183-6","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with rituximab: analyses of global postmarketing safety data and long-term clinical trial data","volume":"7","author":"Emery","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2022-223715_bib18","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223715_bib19","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.berh.2019.03.011","article-title":"Malignancy and rheumatoid arthritis: epidemiology, risk factors and management","volume":"32","author":"De Cock","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1136\/ard-2022-223715_bib20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2018.4537","article-title":"Cardiovascular risk factors associated with venous thromboembolism","volume":"4","author":"Gregson","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1136\/ard-2022-223715_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/annrheumdis-2020-218419","article-title":"Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden","volume":"80","author":"Molander","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223715_bib22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/OARRR.S284757","article-title":"Venous thromboembolism in rheumatoid arthritis: the added effect of disease activity to traditional risk factors","volume":"14","author":"Omair","year":"2022","journal-title":"Open Access Rheumatol"},{"key":"10.1136\/ard-2022-223715_bib23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological dmards: a systematic literature review Informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223715_bib24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223715_bib25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40264-020-00904-9","article-title":"An integrated analysis of the safety of tofacitinib in psoriatic arthritis across phase III and long-term extension studies with comparison to real-world observational data","volume":"43","author":"Burmester","year":"2020","journal-title":"Drug Saf"},{"key":"10.1136\/ard-2022-223715_bib26","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"}],"updated-by":[{"DOI":"10.1136\/ard-2022-223715corr1","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000}}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724129810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724129810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-223715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:40:58Z","timestamp":1739522458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724129810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0003496724129810"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-223715","relation":{"erratum":[{"id-type":"doi","id":"10.1136\/ard-2022-223715corr1","asserted-by":"object"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-223715","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The authors. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}